Current Editions
FDA’s proposal is more ambitious than policies implemented in Australia, China, U.K., but could take years to implement
Regulation
Selective mTORC1 inhibition emerges as a strategy to improve safety and efficacy in rare epilepsy disorder
Product Development
As it approaches its tenth birthday, the Parker Institute is showing the power of focusing on translation
Discovery & Translation
With a new fund 40% larger than its last, the life sciences investor will press ahead with two discrete investment models
Finance
French VC firm looks to deliver growth capital to European biotechs
Finance
Product Development
Second Phase II success supports targeted approach in refractory patients
Emerging Company Profile
Stipple is mapping the cancer surfaceome at epitope-level resolution to generate tumor-specific binders that spare healthy tissue
Data Byte
April’s first week has already matched or exceeded the full-quarter total seen in three quarters since 2019
Discovery & Translation
Plus: A map of pain circuitry, a safer mu-opioid receptor agonist, and a small molecule that could prevent weigh rebound after GLP-1s
Politics, Policy & Law
Instead of a $10M penalty for conducting first-in-human trials overseas, reauthorized PDUFA would cut fees by $2M for domestic FIH trials
Deals
With little near-term competition, hyperphagia treatment figures to continue sales growth
Deal brings two clinical programs and a conjugation platform to an oncology portfolio with little behind its anchor ADC
How South Korea and Japan are building biotech ecosystems with growing global reach
Finance
Plus: Venture rounds for Stipple, Sidewinder and Life; a follow-on for Forte; and more
Biopharma Stock Performers
Use BioCentury's interactive dashboard to view top-performing biopharma stocks for the day and the week.
Product Development
BioCentury ISSN 1097-7201